[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vera Therapeutics Inc Cl A (VERA)

Vera Therapeutics Inc Cl A (VERA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,493,380
  • Shares Outstanding, K 72,063
  • Annual Sales, $ 0 K
  • Annual Income, $ -299,610 K
  • EBIT $ -416 M
  • EBITDA $ -420 M
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.51

Options Overview Details

View History
  • Implied Volatility 103.99% (-7.31%)
  • Historical Volatility 59.72%
  • IV Percentile 74%
  • IV Rank 57.49%
  • IV High 142.89% on 07/01/26
  • IV Low 51.39% on 09/02/25
  • Expected Move (DTE 21) 6.04 (17.83%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 742
  • Volume Avg (30-Day) 2,335
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 31,204
  • Open Int (30-Day) 30,521
  • Expected Range 27.86 to 39.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.72
  • Number of Estimates 6
  • High Estimate $-1.60
  • Low Estimate $-1.83
  • Prior Year $-1.26
  • Growth Rate Est. (year over year) -36.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.86 +16.67%
on 08/13/26
36.96 -8.90%
on 08/26/26
+0.35 (+1.05%)
since 07/28/26
3-Month
28.86 +16.67%
on 08/13/26
44.87 -24.96%
on 06/30/26
-2.19 (-6.11%)
since 05/28/26
52-Week
21.20 +58.82%
on 08/29/25
56.05 -39.93%
on 12/24/25
+11.38 (+51.05%)
since 08/28/25

Most Recent Stories

More News
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression. Alignment with FDA on earlier...

VERA : 33.74 (-2.49%)
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results...

VERA : 33.74 (-2.49%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation...

VERA : 33.74 (-2.49%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

VERA : 33.74 (-2.49%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

VERA : 33.74 (-2.49%)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee)...

VERA : 33.74 (-2.49%)
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer...

VERA : 33.74 (-2.49%)
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

Vera Therapeutics announces appointment of Nancy Boman as Chief Regulatory Officer and planned retirement of William Turner ...

VERA : 33.74 (-2.49%)
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy...

VERA : 33.74 (-2.49%)
3 Biotech Firms With Major Potential Catalysts in the Coming Months

The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms.

KRYS : 350.00 (-2.09%)
VERA : 33.74 (-2.49%)
ADMA : 9.47 (-0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 38.77
2nd Resistance Point 37.73
1st Resistance Point 36.17
Last Price 33.74
1st Support Level 33.57
2nd Support Level 32.53
3rd Support Level 30.97

See More

52-Week High 56.05
Fibonacci 61.8% 42.74
Fibonacci 50% 38.63
Fibonacci 38.2% 34.51
Last Price 33.74
52-Week Low 21.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.